Completed PHASE1 INTERVENTIONAL 2-arm NCT02822105

Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers

Phase 1 Clinical Study To Investigate The Safety And Immunogenicity Of The H3N2 (A/Brisbane/10/2007) M2SR Monovalent Influenza Vaccine

Sponsor: FluGen Inc

Conditions Flu

Interventions Placebo the H3N2 M2SR monovalent influenza vaccine

Updated 8 times since 2017 Last updated: Aug 7, 2020 Started: Jun 30, 2016 Primary completion: Apr 30, 2017 Completion: Nov 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02822105, this PHASE1 trial focuses on Flu and remains completed. Sponsored by FluGen Inc, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
Aug 2019 — Sep 2020 [monthly]

Unknown Status PHASE1

Status: Active Not Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Aug 2019 [monthly]

Active Not Recruiting PHASE1
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

FluGen Inc

Data source: FluGen Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lenexa, United States